MOUNTAIN VIEW, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, will present at the iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025, held on September 16-17, 2025. Mr. Bagai will discuss RenovoRx’s ongoing commercialization effo ...